Mucinous tubular and spindle cell carcinoma (MTSCC) of the kidney: a detailed study of radiological, pathological and clinical outcomes. (12th March 2015)

• Record Type: Journal Article
• Authors: Kenney, Patrick A.; Vikram, Raghunandan; Prasad, Srinivasa R.; Tamboli, Pheroze; Matin, Surena F.; Wood, Christopher G.; Karam, Jose A.
• Is Part Of: BJU international. Volume 116:Number 1(2015:Jul.)
• Page Start: 85
• Page End: 92
• Publication Date: 2015-03-12
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12992
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main" id="bju12992-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12992-sec-0001" sec-type="section"> <title>Objective</title> <p>To characterise the clinical, radiological and histological features of mucinous tubular and spindle cell carcinoma (MTSCC), as well as oncological outcomes.</p> </sec> <sec id="bju12992-sec-0002" sec-type="section"> <title>Patients and methods</title> <p>This is a single institution retrospective analysis of all patients with MTSCC from 2002 to 2011. Patients were excluded if MTSCC could not be confirmed on pathology re‐review (four patients). Clinical characteristics, pathology, imaging, and outcomes were reviewed for the 19 included patients.</p> </sec> <sec id="bju12992-sec-0003" sec-type="section"> <title>Results</title> <p>The median (range) age at diagnosis was 59 (17–71) years with a female predominance (78.9%). On contrast‐enhanced computed tomography, MTSCC enhanced less than the cortex during the corticomedullary phase. The mean (range) tumour attenuation was 36 (24–48), 67 (41–133), 89 (49–152), and 76 (52–106) Hounsfield units in the pre‐contrast, corticomedullary, nephrographic and excretory phases, respectively. In all, 16 patients were treated with partial (five patients) or radical nephrectomy (11) for pT1 (62.5%), pT2 (31.3%), and pT3a disease (6.3%). One patient underwent active surveillance. Of three patients (13.0%) managed with energy ablation, there was one recurrence that was treated with salvage surgery. One patient (5.3%) had metastatic disease at diagnosis and died from disease 64.7 months later. A patient with a pT2bN0M0 MTSCC with sarcomatoid dedifferentiation developed bone metastases 9.5 months after diagnosis and was alive at 19.0 months. The remainder were free of recurrence or progression.</p> </sec> <sec id="bju12992-sec-0004" sec-type="section"> <title>Conclusion</title> <p>MTSCC is a rare renal cell carcinoma (RCC) variant. In this largest series to date, MTSCC presented at a broad range of ages and displayed a female predilection. Imaging and pathological features of MTSCC display some overlap with papillary RCC. MTSCC is associated with excellent outcomes overall, but is not universally indolent.</p> </sec> </abstract>